Lexeo Therapeutics (LXEO) News Today → America could fall from this event (From Porter & Company) (Ad) Free LXEO Stock Alerts $13.97 +0.41 (+3.02%) (As of 05:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:41 AM | americanbankingnews.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) to Post FY2028 Earnings of $0.07 Per Share, Leerink Partnrs ForecastsMay 9, 2024 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 14.4%Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 14.4%May 9, 2024 | globenewswire.comLexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsMay 7, 2024 | globenewswire.comLexeo Therapeutics to Participate in Upcoming Investor ConferencesApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy AdvancementsApril 26, 2024 | marketbeat.comResearch Analysts Offer Predictions for Lexeo Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LXEO)Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Leerink Partnrs decreased their Q1 2024 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a report issued on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar now expects that the company wilApril 25, 2024 | marketbeat.comLexeo Therapeutics, Inc. Forecasted to Post FY2027 Earnings of ($2.58) Per Share (NASDAQ:LXEO)Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Analysts at Leerink Partnrs issued their FY2027 earnings per share estimates for shares of Lexeo Therapeutics in a note issued to investors on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earApril 24, 2024 | uk.investing.comLexeo Therapeutics secures rights to advance gene therapyApril 22, 2024 | finance.yahoo.comLexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyApril 16, 2024 | marketwatch.comLexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia CardiomyopathyApril 16, 2024 | markets.businessinsider.comLexeo's LX2006 Gene Therapy Gets FDA Fast Track Designation; Stock Up In Pre-marketApril 16, 2024 | finance.yahoo.comLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathyApril 16, 2024 | globenewswire.comLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia CardiomyopathyApril 9, 2024 | seekingalpha.comLexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay OffMarch 14, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)March 13, 2024 | globenewswire.comLexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingMarch 13, 2024 | markets.businessinsider.comOptimistic Outlook for Lexeo Therapeutics with Strong Clinical and Financial Performance Justifying Buy RatingMarch 12, 2024 | markets.businessinsider.comRBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To KnowMarch 11, 2024 | msn.comLexeo Therapeutics announces $95M private equity placementMarch 11, 2024 | globenewswire.comLexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsMarch 11, 2024 | globenewswire.comLexeo Therapeutics Announces Oversubscribed $95.0 Million Equity FinancingFebruary 13, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by AnalystsLexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among bFebruary 6, 2024 | msn.comLexeo Therapeutics Bolsters Leadership with Key HiresFebruary 5, 2024 | msn.comLexeo Therapeutics announces new executive appointmentsFebruary 5, 2024 | finance.yahoo.comLexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsJanuary 29, 2024 | seekingalpha.comLexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer'sJanuary 19, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Forecasted to Earn Q2 2024 Earnings of ($0.71) Per ShareLexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2024 EPS estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Wednesday, January 17th. Leerink Partnrs analyst M. Foroohar expects that the companJanuary 19, 2024 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of "Buy" from AnalystsShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year target price amJanuary 19, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Lexeo Therapeutics, Inc. (LXEO) and Andlauer Healthcare Group (OtherANDHF)January 18, 2024 | marketbeat.comTrading was temporarily halted for "LXEO" at 09:01 AM with a stated reason of "LULD pause."January 18, 2024 | marketbeat.comLexeo Therapeutics, Inc. Expected to Post Q1 2024 Earnings of ($0.71) Per Share (NASDAQ:LXEO)Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for Lexeo Therapeutics in a research note issued on Wednesday, January 17th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post eJanuary 7, 2024 | seekingalpha.comLXEO Lexeo Therapeutics, Inc.January 6, 2024 | markets.businessinsider.comLexeo Therapeutics, Inc. (LXEO) Receives a Buy from RBC CapitalJanuary 3, 2024 | finance.yahoo.comLexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 19, 2023 | seekingalpha.comLexeo gets orphan drug, fast track status for cardiac gene therapyDecember 18, 2023 | markets.businessinsider.comLexeo Therapeutics Says FDA Grants Fast Track And Orphan Drug Designation To LX2020December 18, 2023 | finance.yahoo.comLexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)December 14, 2023 | marketbeat.comLeerink Partnrs Weighs in on Lexeo Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:LXEO)Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Leerink Partnrs issued their FY2023 EPS estimates for Lexeo Therapeutics in a research note issued to investors on Monday, December 11th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings oDecember 14, 2023 | markets.businessinsider.comStable Execution and Positive Clinical Progress Support $19 Price Target for Lexeo TherapeuticsDecember 13, 2023 | finance.yahoo.comLexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical ProgramsDecember 11, 2023 | finance.yahoo.comLexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational HighlightsDecember 8, 2023 | morningstar.comLexeo Therapeutics Inc LXEONovember 8, 2023 | marketbeat.comTrading was temporarily halted for "LXEO" at 09:11 AM with a stated reason of "LULD pause." Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address My system predicted the BA collapse – now it’s issuing an AI warning (Ad)Even after several plane crashes and equipment malfunctions... a congressional hearing... and the worst PR firestorm in recent memory... The FTC's commission chair Lina Khan still deems Boeing (BA), "too big to fail" Click to see why a similar situation is currently brewing in the AI market... LXEO Media Mentions By Week LXEO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼0.110.57▲Average Medical News Sentiment LXEO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼81▲LXEO Articles Average Week Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Editas Medicine News Today Voyager Therapeutics News Today Fate Therapeutics News Today iTeos Therapeutics News Today C4 Therapeutics News Today Taysha Gene Therapies News Today Ocugen News Today Alvotech News Today Allogene Therapeutics News Today Replimune Group News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
